Get started
Author

Nobuhiko Seki

Observed name: Seki, Nobuhiko
ORCID: 0000-0002-6562-1137
Observed ORCID: 0000-0002-6562-1137
OpenAlex ID: A5062523486
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al. · Cancer Research Communications · 2
PDF
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)
2025 · Masashi Ishihara, Takahisa Kawamura, et al. · Therapeutic Advances in Medical Oncology · 2
Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment
2026 · Kei Morikawa, Saori Takata, et al. · Scientific Reports · 1
PDF
Positioning of erlotinib plus ramucirumab therapy in current clinical practice for EGFR-mutated non-small cell lung cancer
2026 · Masashi Ishihara, Nobuhiko Seki · Shanghai Chest
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis
2026 · Masashi Ishihara, Takahisa Kawamura, et al. · JTO Clinical and Research Reports
An Update on Therapeutic Strategies for HER2-Mutated Non-Small Cell Lung Cancer
2025 · Masashi Ishihara, Shigeru Tanzawa, et al. · Journal of Clinical Question
PDF
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Table 4 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Table 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Table 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study
2025 · Tomonori Makiguchi, Hisashi Tanaka, et al. · Cancer Treatment and Research Communications
Works count: 25
Citation count: 5
H-index: 2
I10-index:
Year
Topic
Type